BioStock

Prenumeration

BioStock Studio: Abliva on the 200 MSEK financing round

2022-06-01 10:44:11

Yesterday, biotech Abliva, whose focus is on primary mitochondrial diseases, announced that it has decided on a 200 million SEK financing round. The funding consists of a directed share issue of approximately 150 million SEK and a rights issue of approximately 50 million SEK. Abliva's CEO Ellen Donnelly told BioStock about raising capital under challenging market conditions and how the proceeds will be used.

See the interview with Ellen Donnelly, in English, at biostock.se:

https://www.biostock.se/en/2022/06/abliva-on-the-200-msek-financing-round/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden